Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)

Polymorphic Light Eruption Clinical Trial

Official title:
A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE)

Status Completed

Clinical Trial Summary

This study was to evaluate the safety and efficacy of afamelanotide in patients suffering from polymorphic light eruption (PLE).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04704713
Study type	Interventional
Source	Clinuvel Pharmaceuticals Limited
Contact
Status	Completed
Phase	Phase 3
Start date	May 5, 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Recruiting	`NCT04985526` - Skin Microbiome and Polymorphic Light Eruption	N/A
Completed	`NCT00871052` - Calcipotriol and Polymorphic Light Eruption	N/A
Completed	`NCT00555178` - Regulatory T Cells (Tregs) in Polymorphic Light Eruption	N/A
Completed	`NCT05320315` - Protective Effect Assessment of Foto Ultra Isdin Solar Allergy Fusion Fluid on the UVA Induced PLE	N/A
Completed	`NCT00549588` - Sunscreen and After-sun-lotion Protection in Polymorphic Light Eruption	N/A
Terminated	`NCT01595893` - Vitamin D Supplementation in Polymorphic Light Eruption	Phase 3